This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Are Achillion, Inovio Buyout Targets, Like Merck's Idenix?: StockTwits

Stocks in this article: IDIX ACHN INO MRK JNJ ABBV

NEW YORK (TheStreet) -- Investors are betting on which company will be the next Idenix  (IDIX) -- a hot target for a buyout. The favorites on StockTwits.com? Achillion Pharmaceuticals  (ACHN) and Inovio  (INO).

Drug giant Merck  (MRK) announced Monday that it would acquire Idenix for $3.85 billion. The company's "promising portfolio" of hepatitis C treatments was the main driver of the deal, according to Merck's Research Laboratories president.

Many investors speculate that the $24.50 per share cash deal -- a more than 233% premium over the prior closing price -- was so high because of a bidding war with Merck competitors. And they believe the losing bidders -- reportedly Johnson & Johnson  (JNJ) and Abbvie  (ABBV) -- could now try to secure Idenix competitors with promising hep C drugs of their own.

$MRK need not have paid 4x the share price for $IDIX...Bidding war is absolutely active behind the scenes. $ACHN and $IDIX pretty similar. ? Golden Gate Sings (@goldengatesings2) Jun. 10 at 12:12 PM

$ACHN Abbvie and J&J are currently completely locked out of the Hep C market....ACHN will get its premium is my bet. ? Golden Gate Sings (@goldengatesings2) Jun. 10 at 12:11 PM

Achillion Pharmaceuticals has several Hepatitis C treatments in human trials. The company announced today that it began dosing patients with chronic hepatitis C with its ACH-3422 drug and will report the results in the fall. It also announced that the FDA removed a clinical hold on sovaprevir, another hepatitis C treatment. Sovaprevir is in Phase 2 clinical trials and can resume dosing patients with hepatitis C. The company can also dose some healthy control patients, but not as many times, according to the FDA.

The stock surged more than 53% after the news.

All the A named bios came back from FDA adversity $ARIA $ACHN next is $AFFY if drug comes back upside over 1,000% ? So Generous (@sogenerous) Jun. 10 at 12:12 PM

Inovio Pharmaceuticals also has several hepatitis vaccines, also known as immunotherapies. It has a hepatitis C vaccine in Phase 1 human trials and a hepatitis B vaccine in preclinical trials. The company's pipeline also includes vaccines for HIV, influenza, malaria and HPV strains that cause cervical cancer and head and neck cancers.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,786.60 +8.45 0.05%
S&P 500 2,064.91 +3.68 0.18%
NASDAQ 4,757.8120 +9.4160 0.20%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs